U.S. markets open in 4 hours 32 minutes

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.6500+0.0200 (+1.23%)
At close: 04:00PM EDT
1.6000 -0.05 (-3.03%)
Pre-Market: 04:07AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.6300
Bid0.0000 x 3000
Ask0.0000 x 3000
Day's Range1.6050 - 1.6800
52 Week Range1.1900 - 7.5300
Avg. Volume1,900,813
Market Cap108.818M
Beta (5Y Monthly)0.48
PE Ratio (TTM)N/A
EPS (TTM)-1.4090
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.41
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CTMX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CytomX Therapeutics, Inc.
    The Argus High-Yield Model PortfolioValue stocks -- a market segment that includes high-yield stocks -- are outperforming growth stocks in 2022 for the first time since 2016. Indeed, for the past decade, the performance record has favored growth. In nine of the past 10 years, growth stocks have topped value stocks. But the tide may be turning. The rollout of COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past year. Now, the Federal Reserve lifting interest rates to fend off inflation, which will likely cap multiple expansion for growth companies. Regardless, the value sector is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.1%, compared to the 0.8% current yield on the iShares Russell 1000 Growth Index ETF. For our High-Yield Theme Model Portfolio, we are seeking stocks with yields of at least 3.0%. This moves us deep into the value segment of the market.
    Fair Value
    Economic Moat
    13 hours agoArgus Research
View more
  • Motley Fool

    CytomX Therapeutics (CTMX) Q2 2022 Earnings Call Transcript

    Before we begin, I'd like to remind everyone that during this call, we will be making forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict and many of which are outside of our control.

  • Zacks

    CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

    CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.78% and 1.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

    - Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated therapeutics, extending cash runway to 2025 - - New INDs for two next-generation product candidates anticipated in 2023 - - Continued progress with partnered clinical programs: CX-904 (Amgen, Phase 1), BMS-986249 (Bristol Myers Squibb, Phase 2), and CX-2029 (AbbVie, Phase 2) - SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: